IMMUNOVANT
Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Its investigational product candidate, IMVT-1401 (formerly known as RVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). We believe that this product has the potential to address a variety of IgG-mediated autoimmune diseases as a subcutaneous injection.
IMMUNOVANT
Social Links:
Industry:
Biotechnology Pharmaceutical
Founded:
2018-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.immunovant.com
Total Employee:
101+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
200 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Domain Not Resolving Apache Microsoft Exchange Online Amazon
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Checkmate Pharmaceuticals
Checkmate Pharma is a clinical stage biopharmaceutical company developing a new approach for cancer immunotherapy.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Current Employees Featured
Stock Details
Investors List
Roivant Sciences
Roivant Sciences investment in Post-IPO Equity - Immunovant
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Post-IPO Equity - Immunovant
Key Employee Changes
| Date | New article |
|---|---|
| 2022-01-25 | Immunovant Appoints Mark Levine as Chief Legal Officer |
| 2021-09-15 | Immunovant Appoints Renee Barnett as Chief Financial Officer |
Official Site Inspections
http://www.immunovant.com Semrush global rank: 852.69 K Semrush visits lastest month: 44.46 K
- Host name: ec2-54-208-101-55.compute-1.amazonaws.com
- IP address: 54.208.101.55
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Immunovant"
Our Leadership :: Immunovant, Inc. (IMVT)
Pete Salzmann, M.D., MBA. Chief Executive Officer. Pete Salzmann, M.D., MBA, is the Chief Executive Officer of Immunovant and a member of our board of directors. From November 2018 to June 2019, he served as a Global Brand …See details»
Immunovant - Crunchbase Company Profile & Funding
Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Its investigational product …See details»
About Us - Immunovant, Inc. (IMVT)
Immunovant’s two investigational products, IMVT-1402 and batoclimab, are novel, fully human, monoclonal antibodies that target FcRn and may reduce harmful immunoglobulin G (IgG) autoantibodies, which are common causes of …See details»
Immunovant, Inc. (IMVT) Company Profile & Facts
See the company profile for Immunovant, Inc. (IMVT) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and their ...See details»
Immunovant, Inc. - AnnualReports.com
Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, …See details»
Immunovant, Inc. Company Profile | New York, NY | Competitors ...
Find company research, competitor information, contact details & financial data for …See details»
Immunovant, Inc. (IMVT) Company Profile & Facts - Yahoo Finance
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal …See details»
Immunovant, Inc. (IMVT) Company Profile & Overview - Stock …
Dec 24, 2024 Immunovant, Inc., a clinical-stage biopharmaceutical company, develops …See details»
Immunovant Inc Company Profile - GlobalData
Immunovant Inc (Immunovant) is a biopharmaceutical company that focus on developing …See details»
Immunovant Company Profile 2024: Stock Performance
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling …See details»
Company Information :: Immunovant, Inc. (IMVT)
Immunovant, Inc. 320 W 37th Street 6th Floor New York, NY 10018 . INVESTOR RELATIONS. …See details»
Immunovant, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a …See details»
Immunovant Company Profile - Craft
Oct 29, 2024 Immunovant is a biopharmaceutical company focused on autoimmune …See details»
Immunovant - Funding, Financials, Valuation & Investors
Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives …See details»
Immunovant - Contacts, Employees, Board Members, Advisors
Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives …See details»
Values & Culture :: Immunovant, Inc. (IMVT)
At Immunovant, you will be engaged intellectually through challenging work, you will apply your …See details»
Immunovant - Overview, News & Similar companies | ZoomInfo.com
Immunovant, Inc. (NASDAQ:IMVT) CTO Jay S. Stout Sells 2,813 Shares - Defense World …See details»
We Think Immunovant (NASDAQ:IMVT) Can Afford To Drive …
2 days ago In September 2024, Immunovant had US$473m in cash, and was debt-free. In the …See details»
Immunovant (IMVT) Earnings Date and Reports 2025 - MarketBeat
Immunovant announced Q2 2025 earnings on November 7, 2024, reporting an EPS of -$0.74, …See details»
For Investors :: Immunovant, Inc. (IMVT)
Oct 29, 2024 Immunovant, Inc. 320 W 37th Street 6th Floor New York, NY 10018 . Investor …See details»